Abstract
We report a population-based study of patterns of care and survival for people with acute leukaemia diagnosed at age 15–29 years during 1984–94 in regions of England and Wales covered by specialist leukaemia registries. There were 879 patients: 417 with acute lymphoblastic leukaemia (ALL) and 462 with acute myeloid leukaemia (AML). For ALL, actuarial survival rates were 43% at 5 years after diagnosis and 37% at 10 years. Survival improved significantly between 1984–88 and 1989–94 for those aged 15–19 at diagnosis. Patients entered in national clinical trials and those not entered had similar survival rates. Survival rates were similar at teaching and non-teaching hospitals and at hospitals treating different numbers of study patients per year. For AML, survival rates were 42% at 5 years after diagnosis and 39% at 10 years. Survival improved significantly between 1984–88 and 1989–94. Patients entered in the Medical Research Council AML10 trial had a higher survival rate than those who were in the earlier AML9 trial. Survival did not vary with category of hospital. We conclude that survival has improved for adolescents and young adults with acute leukaemia but that there is at present no evidence that centralized treatment results in a survival benefit for patients in this age group. © 1999 Cancer Research Campaign
Keywords: acute leukaemia, survival rates, place of treatment, clinical trials
Full Text
The Full Text of this article is available as a PDF (86.1 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Chessells J. M., Hall E., Prentice H. G., Durrant J., Bailey C. C., Richards S. M. The impact of age on outcome in lymphoblastic leukaemia; MRC UKALL X and XA compared: a report from the MRC Paediatric and Adult Working Parties. Leukemia. 1998 Apr;12(4):463–473. doi: 10.1038/sj.leu.2400959. [DOI] [PubMed] [Google Scholar]
- Hann I. M., Stevens R. F., Goldstone A. H., Rees J. K., Wheatley K., Gray R. G., Burnett A. K. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council. Blood. 1997 Apr 1;89(7):2311–2318. [PubMed] [Google Scholar]
- Haward R. A. Establishing cancer units. Br J Cancer. 1995 Sep;72(3):531–534. doi: 10.1038/bjc.1995.369. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kerr D. J., Griffiths R., Edwards B. Delivering cancer care: a model from the West Midlands. Br J Cancer. 1996 Sep;74(5):667–669. doi: 10.1038/bjc.1996.419. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Proctor S. J. Acute lymphoblastic leukaemia in adults: the case for a strategic shift in study approach. Br J Haematol. 1994 Oct;88(2):229–233. doi: 10.1111/j.1365-2141.1994.tb05011.x. [DOI] [PubMed] [Google Scholar]
- Proctor S. J., Taylor P. R., Stark A., Carey P. J., Bown N., Hamilton P. J., Reid M. M. Evaluation of the impact of allogenic transplant in first remission on an unselected population of patients with acute myeloid leukaemia aged 15-55 years. The Northern Regional Haematology Group. Leukemia. 1995 Jul;9(7):1246–1251. [PubMed] [Google Scholar]
- Proctor S. J., Taylor P., Thompson R. B., Finney R., Reid M. M., Hamilton P. J., Saunders P., Fail B., Dickinson A., Paul B. Acute lymphoblastic leukaemia in adults in the northern region of England--a study of 75 cases. Q J Med. 1985 Nov;57(223):761–774. [PubMed] [Google Scholar]
- Schneider U., van Lessen A., Huhn D., Serke S. Two subsets of peripheral blood plasma cells defined by differential expression of CD45 antigen. Br J Haematol. 1997 Apr;97(1):56–64. doi: 10.1046/j.1365-2141.1997.d01-2115.x. [DOI] [PubMed] [Google Scholar]
- Secker-Walker L. M., Prentice H. G., Durrant J., Richards S., Hall E., Harrison G. Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukaemia on MRC trial UKALL XA. MRC Adult Leukaemia Working Party. Br J Haematol. 1997 Mar;96(3):601–610. doi: 10.1046/j.1365-2141.1997.d01-2053.x. [DOI] [PubMed] [Google Scholar]
- Selby P., Gillis C., Haward R. Benefits from specialised cancer care. Lancet. 1996 Aug 3;348(9023):313–318. doi: 10.1016/s0140-6736(96)02482-8. [DOI] [PubMed] [Google Scholar]
- Stiller C. A. Centralised treatment, entry to trials and survival. Br J Cancer. 1994 Aug;70(2):352–362. doi: 10.1038/bjc.1994.306. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Stiller C. A., Draper G. J. Treatment centre size, entry to trials, and survival in acute lymphoblastic leukaemia. Arch Dis Child. 1989 May;64(5):657–661. doi: 10.1136/adc.64.5.657. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Stiller C. A., Eatock E. M. Survival from acute non-lymphocytic leukaemia, 1971-88: a population based study. Arch Dis Child. 1994 Mar;70(3):219–223. doi: 10.1136/adc.70.3.219. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Stiller C. A. Population based survival rates for childhood cancer in Britain, 1980-91. BMJ. 1994 Dec 17;309(6969):1612–1616. doi: 10.1136/bmj.309.6969.1612. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Warrell R. P., Jr, Frankel S. R., Miller W. H., Jr, Scheinberg D. A., Itri L. M., Hittelman W. N., Vyas R., Andreeff M., Tafuri A., Jakubowski A. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med. 1991 May 16;324(20):1385–1393. doi: 10.1056/NEJM199105163242002. [DOI] [PubMed] [Google Scholar]
- Youngson J. H., Jones J. M., Chang J. G., Harris M., Banergee S. S. Treatment and survival of lymphoid malignancy in the north-west of England: a population-based study. Br J Cancer. 1995 Sep;72(3):757–765. doi: 10.1038/bjc.1995.406. [DOI] [PMC free article] [PubMed] [Google Scholar]